BR112020025296A2 - Métodos e composições para tratar e/ou prevenir progressão e/ou início de neurodegeneração relacionada à idade - Google Patents

Métodos e composições para tratar e/ou prevenir progressão e/ou início de neurodegeneração relacionada à idade Download PDF

Info

Publication number
BR112020025296A2
BR112020025296A2 BR112020025296-4A BR112020025296A BR112020025296A2 BR 112020025296 A2 BR112020025296 A2 BR 112020025296A2 BR 112020025296 A BR112020025296 A BR 112020025296A BR 112020025296 A2 BR112020025296 A2 BR 112020025296A2
Authority
BR
Brazil
Prior art keywords
aminosterol
dose
subject
pharmaceutical composition
derivative
Prior art date
Application number
BR112020025296-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Zasloff
Denise Barbut
Original Assignee
Enterin, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin, Inc. filed Critical Enterin, Inc.
Publication of BR112020025296A2 publication Critical patent/BR112020025296A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR112020025296-4A 2018-06-13 2019-06-13 Métodos e composições para tratar e/ou prevenir progressão e/ou início de neurodegeneração relacionada à idade BR112020025296A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862684496P 2018-06-13 2018-06-13
US62/684,496 2018-06-13
PCT/US2019/036946 WO2019241503A1 (en) 2018-06-13 2019-06-13 Methods and compositions for treating and/or preventing the progression and/or onset of age-related neurodegeneration

Publications (1)

Publication Number Publication Date
BR112020025296A2 true BR112020025296A2 (pt) 2021-03-09

Family

ID=68838925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020025296-4A BR112020025296A2 (pt) 2018-06-13 2019-06-13 Métodos e composições para tratar e/ou prevenir progressão e/ou início de neurodegeneração relacionada à idade

Country Status (11)

Country Link
US (2) US20190381071A1 (https=)
EP (1) EP3806862A4 (https=)
JP (1) JP2021527090A (https=)
KR (1) KR20210009422A (https=)
CN (1) CN112566641A (https=)
AU (1) AU2019285065A1 (https=)
BR (1) BR112020025296A2 (https=)
CA (1) CA3103463A1 (https=)
MX (1) MX2020013614A (https=)
SG (1) SG11202012343TA (https=)
WO (1) WO2019241503A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
EP3829587A4 (en) * 2018-08-03 2022-07-20 Enterin, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN AND GUESS DISORDERS
WO2020028791A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Low dosage intranasal aminosterol dosage forms and methods of using the same
CN110827282B (zh) * 2020-01-13 2020-04-10 南京慧脑云计算有限公司 一种基于磁共振成像的脑白质纤维束示踪分析方法及系统
CN111110873A (zh) * 2020-02-24 2020-05-08 苏州欣影生物医药技术有限公司 一种磁共振/核医学双模态分子影像探针的制备方法
CN111528839B (zh) * 2020-05-29 2023-06-23 北京京东方健康科技有限公司 睡眠检测方法和装置、助眠设备和方法
WO2022244929A1 (ko) * 2021-05-21 2022-11-24 애니머스큐어 주식회사 이노토디올을 포함하는 근육 질환의 예방 또는 치료용 조성물
WO2025054408A1 (en) * 2023-09-07 2025-03-13 NeuroTherapia, Inc. Methods of treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
JP2010538072A (ja) * 2007-09-06 2010-12-09 ジェナエラ コーポレイション 糖尿病を治療する方法
WO2011066260A2 (en) * 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same

Also Published As

Publication number Publication date
WO2019241503A1 (en) 2019-12-19
MX2020013614A (es) 2021-05-27
CN112566641A (zh) 2021-03-26
JP2021527090A (ja) 2021-10-11
US20210252023A1 (en) 2021-08-19
EP3806862A4 (en) 2022-07-06
SG11202012343TA (en) 2021-01-28
EP3806862A1 (en) 2021-04-21
US20190381071A1 (en) 2019-12-19
KR20210009422A (ko) 2021-01-26
AU2019285065A1 (en) 2021-01-07
CA3103463A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
BR112020025296A2 (pt) Métodos e composições para tratar e/ou prevenir progressão e/ou início de neurodegeneração relacionada à idade
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
US12201631B2 (en) Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome
Nance Spinal muscular atrophy
JP6957602B2 (ja) 神経変性疾患のための治療薬
ES2327521T3 (es) Procedimientos de prevencion, tratamiento y diagnostico de trastornos de la agregacion de proteinas.
Gibb et al. Pathological report of four patients presenting with cranial dystonias
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
TWI428130B (zh) 治療急性躁狂症之藥學組成物及方法
JP7352542B2 (ja) 運動失調を処置するためのリルゾールプロドラッグの使用
JP2021527090A5 (https=)
JP2012500801A (ja) Ｃｎｓ疾患の治療法
KR20200074170A (ko) 신경퇴행성 질병에 대한 치료제
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
EP3829587A1 (en) Compositions and methods for treating brain-gut disorders
JPWO2019241503A5 (https=)
US20210315907A1 (en) Compositions and methods for treating brain-gut disorders
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
WO2023146838A1 (en) Methods for treating or preventing neurodegenerative disease using a combination of aminosterols and an insulin compound
Acton Tryptamines—Advances in Research and Application: 2012 Edition
Lim et al. Parkinson's disease and pain—Nondopaminergic mechanisms are likely to be important too
Malaspina et al. Disorders of the Motor Cells: The Motor Neuron Diseases
Feldman et al. Motor neuron diseases
Lopez et al. Approach to pediatric neuromuscular disorders
US20200038417A1 (en) Methods and compositions for treating cognitive impairment

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.